Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma

Next Previous
Search
Trial Profile

A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AO 176 (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary)
  • Indications Haematological malignancies; Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Arch Oncology

    • Most Recent Events

    • 21 Aug 2023 Status changed from active, no longer recruiting to completed.
    • 03 Aug 2022 Status changed from recruiting to active, no longer recruiting.
    • 14 Apr 2022 Planned number of patients changed from 102 to 157.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top